Key Drivers
- Strong Liquidity
- Modest Returns
- Equity Funding
AIAI Summary
BLLN's 64% revenue growth, 70% gross margin and new oncology offerings signal a credible shift toward scalable profitability, but its extreme valuation requires sustained adoption, reimbursement progress and stronger free-cash-flow conversion; investors should wait for evidence that new products translate into durable, reimbursed revenue before underwriting further upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Modest Returns
- •Equity Funding
BLLN has exceptional liquidity and improving margins, but modest returns, equity-funded cash growth, and an extreme valuation make the shares high risk at current levels.
Price Behavior
Key Price Behavior Insights:
- •Higher-range trend
- •Resistance rejection
- •Support watch
BLLN remains bullish above $100–101 but is stretched after retreating from $110–111 resistance, with a break below $95–97 signaling reversal risk.
Pulled back from $110.67 to $105.92 after a recent rally
Sentiment & News
Key News Insights:
- •Test expansion
- •Investor outreach
- •Insider disposals
BillionToOne expanded its liquid-biopsy offerings and investor outreach, but significant insider selling may weigh on sentiment.
Product momentum is positive, though insider sales could temper near-term investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings